Original Article
Cardiac Involvement in Fabry's Disease

https://doi.org/10.1016/j.hlc.2005.09.007Get rights and content

Clinical Fabry's disease is due to any of multiple mutations in the X-linked α-galactosidase gene. These mutations are kindred-specific, often spontaneous, and produce varying degrees of functional enzyme deficiency resulting in deposits of specific glycosphingolipid (cerumide), especially in the vasculature, kidneys, heart and reticuloendothelial tissue. Disease frequency has probably been over-estimated at 1/40,000; so few centres have developed clinical experience of the disease, though the disease has been identified in all major racial groups.

References (2)

  • J. Galanos et al.

    Clinical features of Fabry's disease in Australian patients

    Int Med J

    (2002)
  • C.M. Eng et al.

    Safety and efficacy of recombinant human alpha-galactosidase. A replacement therapy in Fabry's disease

    N Eng J Med

    (2001)

Cited by (0)

View full text